First Manhattan CO Viking Therapeutics, Inc. Transaction History

First Manhattan CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $2,088 - $11,340	120 New	120 $9,000
Q2 2022 Aug 15, 2022	BUY	$2.11 - $3.15 $844 - $1,260	400 Added 40.0%	1,400 $4,000
Q2 2021 Aug 16, 2021	BUY	$5.19 - $6.73 $5,190 - $6,730	1,000 New	1,000 $5,000
Q4 2018 Jan 30, 2019	SELL	$7.16 - $16.21 $1.45 Million - $3.27 Million	-201,853 Closed	0 $0
Q3 2018 Oct 15, 2018	SELL	$9.7 - $19.65 $3.23 Million - $6.54 Million	-332,900 Reduced 62.25%	201,853 $3.52 Million
Q2 2018 Aug 01, 2018	BUY	$3.88 - $12.74 $450,080 - $1.48 Million	116,000 Added 27.7%	534,753 $5.07 Million
Q1 2018 Apr 20, 2018	BUY	$4.11 - $6.93 $1.72 Million - $2.9 Million	418,753 New	418,753 $1.83 Million

474

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.18B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.